Medical disclaimer

Durvalumab plus FLOT chemotherapy around surgery for resectable stomach and junction cancer

In the MATTERHORN trial, adding durvalumab (an immunotherapy drug) to FLOT chemotherapy before and after surgery gave better event-free survival than FLOT with placebo in adults with resectable gastric or gastroesophageal junction cancer. Nordwest Clinic (Krankenhaus) in Frankfurt appears only as an author affiliation, and the abstract does not say where the patients were treated.

8 min read

Prepared by Bookimed editorial team

Medical content and care coordination

← All research summaries
Published research, not an individual patient story.

The named clinic is an author affiliation. The study patients were not established as patients treated at that clinic.

Key takeaways

  • The trial compared durvalumab plus FLOT with placebo plus FLOT in adults with resectable gastric or gastroesophageal junction adenocarcinoma.
  • Two-year event-free survival was 67.4% with durvalumab and 58.5% with placebo.
  • Two-year overall survival was 75.7% with durvalumab and 70.4% with placebo, and the abstract reports P = 0.03 for this, above its stated significance threshold of P < 0.0001.
  • Adverse events of grade 3 or 4 were reported in 71.6% of the durvalumab group and 71.2% of the placebo group.
  • Group results are not a forecast for any one patient, and the abstract does not say where patients were treated.

The question this study addresses

MATTERHORN was a phase 3, multinational, double-blind randomized trial. Participants were assigned 1:1 to durvalumab or placebo together with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) chemotherapy. The primary end point was event-free survival, and the secondary end points included overall survival and pathological complete response. One author lists Krankenhaus Nordwest in Frankfurt, but the abstract does not say where patients were treated, and the trial was multicentre. Bookimed did not run this study.

The situation
Adults with gastric or gastroesophageal junction adenocarcinoma that could be removed by surgery.
The treatment
Durvalumab 1500 mg or placebo every 4 weeks plus FLOT for 4 cycles (2 before and 2 after surgery), then durvalumab or placebo for 10 cycles.

What this evidence cannot establish

  • Nordwest Clinic appears as an author affiliation only. The abstract does not say that any patients were treated there.
  • The abstract does not give subgroup results, quality of life, or the specific treatment sites.
  • The trial was funded by AstraZeneca, and group results cannot predict an individual outcome.

Patient groups in the published study

474 patients · Published study group

Durvalumab plus FLOT chemotherapy before and after surgery

Indication
Resectable gastric or gastroesophageal junction adenocarcinoma
Treatment
Durvalumab 1500 mg plus FLOT for 4 cycles (2 neoadjuvant, 2 adjuvant), then durvalumab for 10 cycles

474 adults in the durvalumab group, followed for a median of 31.5 months.

Adults whose stomach or gastroesophageal junction cancer was considered resectable, meaning it could be removed by surgery.

Durvalumab was given every 4 weeks with FLOT chemotherapy around surgery, followed by durvalumab alone for 10 cycles.

  • Two-year event-free survival (Kaplan-Meier estimate)

    67.4%

    474 patients · Study group

    median follow-up 31.5 months

  • Two-year overall survival

    75.7%

    474 patients · Study group

    median follow-up 31.5 months

  • Pathological complete response

    19.2%

    474 patients · Study group

    not stated

  • Delayed surgery

    10.1%

    474 patients · Study group

    not stated

  • Delayed initiation of adjuvant treatment

    2.3%

    474 patients · Study group

    not stated

Reported risks

  • These are study-wide items: adverse events of grade 3 or 4 were reported in 340 participants (71.6%) in this group, and surgery was delayed in 10.1%.

Limits of this evidence

  • The abstract does not give subgroup results or quality of life.
  • The sites where patients were treated are not stated.

For a clinic assessment

  • Pathology and imaging reports that describe the cancer type and stage.
  • Current medication list and any history of autoimmune disease.

474 patients · Published study group

Placebo plus FLOT chemotherapy before and after surgery (comparison group)

Indication
Resectable gastric or gastroesophageal junction adenocarcinoma
Treatment
Placebo plus FLOT for 4 cycles (2 neoadjuvant, 2 adjuvant), then placebo for 10 cycles

474 adults in the comparison group, followed for a median of 31.5 months.

Adults with the same type of resectable cancer who were assigned by chance to placebo instead of durvalumab.

Placebo was given every 4 weeks with FLOT chemotherapy around surgery, followed by placebo for 10 cycles.

  • Two-year event-free survival (Kaplan-Meier estimate)

    58.5%

    474 patients · Study group

    median follow-up 31.5 months

  • Two-year overall survival

    70.4%

    474 patients · Study group

    median follow-up 31.5 months

  • Pathological complete response

    7.2%

    474 patients · Study group

    not stated

  • Delayed surgery

    10.8%

    474 patients · Study group

    not stated

  • Delayed initiation of adjuvant treatment

    4.6%

    474 patients · Study group

    not stated

Reported risks

  • These are study-wide items: adverse events of grade 3 or 4 were reported in 334 participants (71.2%) in this group, and surgery was delayed in 10.8%.

Limits of this evidence

  • This group is the comparison, not a treatment option offered by the clinic.
  • The sites where patients were treated are not stated.

For a clinic assessment

  • Pathology and imaging reports from the current diagnosis.
  • Prior treatment records, if any, so the coordinator can pass them to the clinic.

Results and limits of the study

Two-year event-free survival was 67.4% with durvalumab and 58.5% with placebo. Two-year overall survival was 75.7% and 70.4%. Pathological complete response was 19.2% and 7.2%. Surgery was delayed in 10.1% and 10.8%, and the start of adjuvant treatment was delayed in 2.3% and 4.6%. The authors concluded that durvalumab plus FLOT gave significantly better event-free survival than FLOT alone. These are group results, not a forecast for any reader.

Risks reported by the source

  • Adverse events of grade 3 or 4 were reported in 340 participants (71.6%) with durvalumab and 334 (71.2%) with placebo.
  • Surgery was delayed in 10.1% with durvalumab and 10.8% with placebo.

Limitations and unknowns

  • Where the patients were treated is not stated.
  • Results for subgroups of patients are not given.
  • Quality of life is not reported in the abstract.
  • Follow-up for the delay and response outcomes is not stated.

What to clarify in your treatment plan

Before booking, ask the clinic whether it offers perioperative immunotherapy with chemotherapy for your type and stage of cancer, and which team would manage it. Ask which records it needs, how side effects are monitored and who to call urgently, and how care would be coordinated with your home oncologist. Ask who will explain how this trial applies to your case.

Nordwest Clinic (Krankenhaus): clinic profile

  • Nordwest Clinic (Krankenhaus) in Frankfurt am Main appears as an author affiliation of the MATTERHORN paper, and the abstract does not say where patients were treated.
  • The clinic profile is available on Bookimed.

The current provider profile is temporarily unavailable. The published evidence on this page remains available.

Safety and recovery: general information

General patient guidance, provided separately from the case evidence. Follow your treating team's instructions.

Possible side effects

  • Common immunotherapy side effects may be mild, such as fatigue, itchy rash, diarrhea, nausea and vomiting, or lower thyroid hormone levels.

    Tell your oncology team about any new symptom so it can be assessed.

  • Immune cells may mistakenly attack healthy tissue, so immunotherapy can cause inflammation that you may feel as one or more side effects.

    Ask the clinic how it recognizes and treats these immune-related effects.

  • These side effects may be serious and even life-threatening.

    Ask the clinic how it handles serious reactions.

Recovery and aftercare

  • Most side effects are temporary, but in rare cases they can cause long-term effects and may linger after the medicine is out of your system.

    Ask how long you would be followed after treatment ends.

  • You might be on immunotherapy for a long time, and side effects can occur at any point during and after treatment.

    Ask the clinic how it follows patients over the full course and afterward.

Suitability and cautions

  • You may be more likely to have a side effect if you take a combination of immunotherapy drugs or have an autoimmune disease.

    Tell the clinic about any combination therapy or autoimmune disease.

  • If you have an autoimmune disease, it is especially important to discuss it with your health care provider before starting treatment.

    Share your autoimmune history with the coordinator before booking.

When to contact the clinic

  • Jaundice, dark urine, pain on the right side of the stomach, vomiting, or easy bleeding or bruising can be signs of hepatitis.

    Contact your oncology team promptly.

  • Diarrhea, bloody, dark or tarry stools, or stomach pain can be signs of colitis.

    Contact your oncology team promptly.

  • Shortness of breath and a bad cough can be signs of lung inflammation (pneumonitis).

    Contact your oncology team promptly.

  • Your oncologist may ask you to call first about inflammatory symptoms, or you may be advised to seek emergency medical care.

    Ask the clinic for its urgent contact route and what to do out of hours.

Request a personal plan from the clinic

Ask Nordwest Clinic about immunotherapy with chemotherapy for resectable stomach cancer

Bookimed passes your records to the clinic and asks whether it can review your case and which team would manage it. The clinic decides whether any treatment suits you.

Ask the clinic for a current, itemized quotation. Published evidence does not establish package inclusions or a current price.

Frequently asked questions

Who ran the MATTERHORN study and where were patients treated?

The abstract does not say where patients were treated. MATTERHORN was a multinational, multicentre phase 3 trial funded by AstraZeneca. One author, Al-Batran, lists Krankenhaus Nordwest in Frankfurt as an affiliation, so Nordwest Clinic is linked to the paper only through that author. Patients were not shown to be treated at this clinic. Bookimed did not run the study.

Did durvalumab improve results in this trial?

Yes, for event-free survival. Two-year event-free survival was 67.4% with durvalumab plus FLOT and 58.5% with placebo plus FLOT. Two-year overall survival was 75.7% and 70.4%, and the abstract reports P = 0.03, above its stated significance threshold of P < 0.0001. These are group results and do not predict what would happen to you.

Were there more side effects with durvalumab?

The abstract reports similar rates of serious adverse events. Events of grade 3 or 4 occurred in 340 participants (71.6%) with durvalumab and 334 (71.2%) with placebo. Surgery was delayed in 10.1% and 10.8%. Immunotherapy side effects may be mild, but they can also be serious, so ask your oncology team how they are monitored and treated.

Can I have this treatment at Nordwest Clinic?

Ask the clinic directly, because this page does not confirm it. The study abstract does not show that patients were treated at Nordwest Clinic, which appears only as an author affiliation. Bookimed can send your records and ask whether the clinic offers immunotherapy with chemotherapy for your cancer and stage, and which team would manage it.

Sources and scope

This page was prepared from the published abstract of the MATTERHORN trial, with safety information paraphrased from the cited Cleveland Clinic and National Cancer Institute quotes. Bookimed did not run the study.

  1. 1. Janjigian et al. – Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.

    Phase 3 multinational double-blind randomized controlled trial · 2025

    Adults with resectable gastric or gastroesophageal junction adenocarcinoma, 474 in each group.

    Follow-up: Median 31.5 months (interquartile range 26.7 to 36.6)

    The page relies on the abstract alone, which does not give the treatment sites, subgroup results, or quality of life.

  2. 2. Cleveland Clinic
  3. 3. National Cancer Institute
  4. 4. National Cancer Institute
  5. 5. Nordwest Clinic (Krankenhaus) on Bookimed

Scope and limitations

  • A research summary is not an individual medical recommendation.
  • Group results describe the study participants, not a forecast for any one patient.

About the editorial team

Bookimed editorial team

Prepared by

Bookimed editorial team

Medical content and care coordination

Bookimed prepares evidence summaries from published medical sources and anonymized care records. The clinic and any doctors named on this page are identified separately in their own sections.

About this page

This page summarizes cited evidence and links to current Bookimed provider profiles. It does not replace an individual diagnosis or treatment plan. Published group results are not a guarantee of your outcome.

Clinic profiles and package availability come from the current Site catalog. Historical costs and research measurements keep their original context.

Report a correction